Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria.
about
Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular PathologyChronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical featuresMast Cell Clonal Disorders: Classification, Diagnosis and ManagementTarget interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growthA clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patientsMast cell leukemia with prolonged survival on PKC412/midostaurin.Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposalAdvances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.Recent advances in the understanding of mastocytosis: the role of KIT mutations.Mastocytosis: state of the art.Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT.Diagnosis and treatment of systemic mastocytosis: state of the art.Osteoporosis and osteopathy markers in patients with mastocytosis.Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.Mastocytosis: pathology, genetics, and current options for therapy.Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.Systemic mastocytosis: bone marrow pathology, classification, and current therapies.Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.Systemic mastocytosis presenting as acute appendicitis: a case report and review of the literature.Mast cells and mastocytosis.Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progressionSynergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816VInvestigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis.Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816HGastrointestinal involvement and manifestations in systemic mastocytosis.Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.Diagnosis, progression patterns and prognostication in mastocytosis.European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives.Mastocytosis: update on pharmacotherapy and future directions.Current treatment options in patients with mastocytosis: status in 2015 and future perspectives.Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease.Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.
P2860
Q24685914-A8F3D1FD-B5F9-44B3-AB99-A7065D8114E6Q27026581-41661C56-90A7-4894-A5BC-88AE540BBA03Q28070386-911BBB97-E256-406E-88A5-C8D6C32E141CQ28828739-ED4CD289-A88F-454A-B289-8F994CECD68FQ33863692-91EEE61A-8555-42F0-9C84-D9C8C04549FAQ33898701-3A289C93-3869-4C93-9AA0-4D3C9138AFE6Q34137971-2CD0AC3C-8342-411A-A8B2-BCAD23AB0A26Q34552564-713811E1-A449-4408-A6A4-8D42B5C2F6B3Q34635424-DDFE37C5-968E-4E42-9AA6-D642566764E9Q34641105-7D068766-F183-496C-9B69-D8290999F869Q34664111-A3377CFE-12C1-43EC-9D8F-9271470F3A53Q35153623-600DEE49-B67C-407A-811C-C192B8541C04Q35203889-8D23CE41-DBBF-4115-ADE3-F2F5C6F57FB6Q35631552-313BBBA0-8304-40F6-A856-7C68057F3575Q35848377-316B8686-3116-4016-B49C-7804A30B1F9DQ35854970-D3708898-FD79-4619-A7D3-0006A469CFACQ35994902-7406AB45-4347-460B-A40D-53637C6C2893Q36182744-013C646B-CE28-44C2-9A66-5A5EBFC3DDACQ36182749-5C45A121-D395-43F1-B3E8-F1A492A9823AQ36406996-E356B665-1E7F-4F23-AE45-0188D4FA2B38Q36730397-FCF29C15-11F9-4C4A-81D0-3933BBC88227Q36797114-28FD078C-F6CB-4C4C-8988-677659F203BDQ36835143-287E97F9-D4DC-4FFB-94B9-515BA68A920FQ36842503-0F9AFDF4-FCBD-4B9C-AB3B-1DD63EFF6B03Q36977300-3550AFA6-8539-41E3-B7B2-3A14F65A6DE2Q37142455-F030A11C-05E7-4331-B56D-7AA4A728F1F8Q37144902-07FD339C-0936-4A6C-9334-8F192BC91C6CQ37325725-238FD1DC-3378-44B5-888A-8554433DD78EQ37450689-05F0806F-3DF9-484C-A96D-8147B3728018Q37462729-E032F614-D601-4426-B954-876A7597F18BQ37611613-866014CB-1A24-4F6D-B94E-2EDDB2B96219Q37693842-8AB98AFD-48FF-402F-8057-065C6FA57D1BQ37810130-A6C2A536-64CE-48DF-A99A-E53701348DD1Q38025156-98CA839A-BF92-4E3A-B884-78924008B7B8Q38062360-0DBECDB2-4725-4619-8213-016A1B0DB296Q38138597-9B08A275-E8B0-4A59-B998-00C498179D6FQ38370943-CC4A2D3A-D0E3-4671-B12C-72AFF5333188Q38582624-51BDCDC7-61DC-4D4C-944F-035186E20A1DQ38661465-987F217A-BC7A-4533-8A5B-496ED83EE567Q38777126-3C8855AC-A3E0-4827-AB3B-6CA6D6A703BF
P2860
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Aggressive systemic mastocytos ...... nd proposed response criteria.
@ast
Aggressive systemic mastocytos ...... nd proposed response criteria.
@en
type
label
Aggressive systemic mastocytos ...... nd proposed response criteria.
@ast
Aggressive systemic mastocytos ...... nd proposed response criteria.
@en
prefLabel
Aggressive systemic mastocytos ...... nd proposed response criteria.
@ast
Aggressive systemic mastocytos ...... nd proposed response criteria.
@en
P2093
P1433
P1476
Aggressive systemic mastocytos ...... nd proposed response criteria.
@en
P2093
Dean D Metcalfe
Hans-Peter Horny
John M Bennett
Luis Escribano
Michel Arock
Peter Valent
Wolfgang R Sperr
P304
P356
10.1016/S0145-2126(02)00168-6
P50
P577
2003-07-01T00:00:00Z